|
|
Post by ryster505 on Sept 14, 2018 20:10:46 GMT -5
Perhaps Mike just made an error and meant end of October which if the 23rd is the end of the month, and not September.
|
|
|
|
Post by nylefty on Sept 14, 2018 20:30:07 GMT -5
On StockTwits, UTHR has 892 "Watchers." MNKD has 33,238! I assume that one of the reasons the latter figure is so high is that many of the bashers have multiple screen names.
|
|
|
|
Post by sportsrancho on Sept 14, 2018 21:29:37 GMT -5
And MNKD is a cult stock. Even when you’re out you’re still in:-) The shorts are just as big of a cult. Waiting for the train wreck.
Your ears at the door. You wonder, you watch, you wait. But if you’re a MNKD long.. you’ve learned that life isn’t about waiting for the storm to pass it’s about learning how to dance in the rain:-) What else can you do ..because with bad news the stock goes down, with good news the stock goes down.
Nothing to do but take a break and stop watching the tape:-)
|
|
|
|
Post by careful2invest on Sept 14, 2018 23:09:14 GMT -5
And MNKD is a cult stock. Even when you’re out you’re still in:-) The shorts are just as big of a cult. Waiting for the train wreck. Your ears at the door. You wonder, you watch, you wait. But if you’re a MNKD long.. you’ve learned that life isn’t about waiting for the storm to pass it’s about learning how to dance in the rain:-) What else can you do ..because with bad news the stock goes down, with good news the stock goes down. Nothing to do but take a break and stop watching the tape:-) Great observation/analogy/explanation/advice Sports, of what it takes to be Long MNKD!! We're definitely in it for the long haul!! Al Mann knew what he had! We knew what he had! Finally, the rest of the world is beginning to find out about it! Great things to come! GLTA LONGS! |
|
|
|
Post by tinkusr8215 on Sept 15, 2018 7:28:23 GMT -5
On StockTwits, UTHR has 892 "Watchers." MNKD has 33,238! I assume that one of the reasons the latter figure is so high is that many of the bashers have multiple screen names. lots of retail that hoped to become rich lots of retail that got burnt and left lots of retail that got burnt and now bashing lots of retails that fall into bashing conspiracy on a 300 million market cap company that runs like a family living on month to month paycheck lots of retail thats bagholding lots of retail that get sucked in every pump and fall into the above 4 groups lots of retail that keep buying a few shares here and there
and thats why.
UTHR is trading @ $120. Most retails and most here as well dont have the concept of Market cap and think UTHR is costly and instead of buying 1 share of UTHR but can buy 100 shares of MNKD. not knowing UTHR has about 40 mil outstanding shares where as MNKD will be close to 200 mill shares.
I recently read a thread here where some one was complaining Liquida was trading @ 15 per share where as MNKD was under $2.
|
|
|
|
Post by sportsrancho on Sept 15, 2018 7:32:13 GMT -5
A case in point .... there has been a lot of false claims being made on Twitter and StockTwits... I read this this morning.
SEC Charges Hedge Fund Adviser With Short-and-Distort Scheme
FOR IMMEDIATE RELEASE
2018-190
Washington D.C., Sept. 12, 2018 —
The Securities and Exchange Commission today charged a hedge fund adviser and his investment advisory firm with illegally profiting from a scheme to drive down the price of San Diego-based Ligand Pharmaceuticals Inc., reaping more than $1.3 million of gains for the adviser and the hedge fund.
The SEC’s complaint charges that Gregory Lemelson and Massachusetts-based Lemelson Capital Management LLC issued false information about Ligand after Lemelson took a short position in Ligand in May 2014 on behalf of The Amvona Fund, a hedge fund he advised and partly owned. Short-sellers profit when the price of stock declines. According to the SEC’s complaint, Ligand’s stock lost more than one-third of its value during the course of Lemelson’s alleged scheme. After establishing his short position, the complaint charges that Lemelson made a series of false statements to shake investor confidence in Ligand, lower its stock price, and increase the value of his position.
The SEC’s complaint, filed in federal court in Massachusetts, alleges that Lemelson used written reports, interviews, and social media to spread untrue claims, including that Ligand was “teetering on the brink of bankruptcy” and that Ligand’s investor relations firm agreed with his view that its flagship Hepatitis C drug, Promacta, was going to become obsolete. Lemelson also allegedly misled investors by citing a European doctor’s negative views on the same Ligand drug without revealing the doctor was Amvona’s largest investor and had a significant financial interest in seeing Ligand’s stock price decline.
“While short-sellers are free to express their opinions about particular companies, they may not bolster those opinions with false statements, which is what we allege Lemelson did here,” said David Becker, an Assistant Director in the SEC’s Division of Enforcement.
The SEC’s complaint charges Lemelson and Lemelson Capital Management with fraud and seeks to have them return allegedly ill-gotten gains with interest and pay monetary penalties. The complaint names the Amvona Fund as a relief defendant and seeks to have it return gains it obtained as a result of Lemelson and his firm’s alleged misconduct.
The SEC’s investigation was conducted by Virginia Rosado Desilets, Sonia Torrico, and Jennifer Clark, and supervised by David A. Becker. The SEC’s litigation will be led by Marc Jones and Al Day.
|
|
|
|
Post by lakers on Sept 15, 2018 14:30:22 GMT -5
The most common types of infections caused by MRSA are skin and soft-tissue infections, bacteremia, infective endocarditis, pneumonia, and osteomyelitis.2 Per current guidelines, oral antimicrobials for the treatment of mild-to-moderate MRSA skin infections include trimethoprim/ sulfamethoxazole, clindamycin, doxycycline, minocycline, and linezolid.
Alternatively, vancomycin tends to be the most common intravenous (IV) agent for empiric coverage of a potentially serious MRSA infection.1 Serious infections caused by MRSA have a high morbidity and mortality, with estimates for mortality as high as 30% to 37% with endocarditis.1 Treatment durations for MRSA infections can vary widely based on the site and source of infection.
|
|
|
|
Post by lakers on Sept 15, 2018 16:44:19 GMT -5
The STAT Study has been published online in Diabetes Technology & Therapeutics. NEJM, Lancet have huge influence. Any plan to publish STAT on them or any other influencers? Do you plan to advance any of : Tacrolimus, PDE5 Inhibitors, Vancomycin, Linezolid, Amphotericin B ? MC: Yes we will be moving several forward. Stat will be avail for free any day if it’s not already. It’s free at www.liebertpub.com/doi/10.1089/dia.2018.0200 |
|
|
|
Post by nylefty on Sept 15, 2018 19:49:18 GMT -5
The STAT Study has been published online in Diabetes Technology & Therapeutics. NEJM, Lancet have huge influence. Any plan to publish STAT on them or any other influencers? Do you plan to advance any of : Tacrolimus, PDE5 Inhibitors, Vancomycin, Linezolid, Amphotericin B ? MC: Yes we will be moving several forward. Stat will be avail for free any day if it’s not already. It’s free at www.liebertpub.com/doi/10.1089/dia.2018.0200I seriously doubt that the NEJM or the Lancet would publish a study that had already appeared in another journal. |
|
|
|
Post by patten1962 on Sept 15, 2018 20:34:45 GMT -5
Perhaps Mike just made an error and meant end of October which if the 23rd is the end of the month, and not September. Totally possible but not what he said. He said "Investor Call" not Earnings call. Today is only the 15th. My hope is UTHR has something big to say, then Mike can talk about it at Cantor! Got that idea from Sports! 😉 |
|
|
|
Post by sportsrancho on Sept 15, 2018 20:49:35 GMT -5
Lol....Correct
If not big, just more clarification on revenues.
|
|
|
|
Post by patten1962 on Sept 16, 2018 4:51:39 GMT -5
Lol....Correct If not big, just more clarification on revenues. How perfect would this be? UTHR says "We are putting 3 drugs on Technosphere"! Then hands Mannkind 120 Million dollars plus royalties. 😁😉🤑 |
|
|
|
Post by sportsrancho on Sept 16, 2018 10:43:25 GMT -5
Lol....Correct If not big, just more clarification on revenues. How perfect would this be? UTHR says "We are putting 3 drugs on Technosphere"! Then hands Mannkind 120 Million dollars plus royalties. 😁😉🤑 If we get three more drugs you’re about 50 million short:-) |
|
|
|
Post by goyocafe on Sept 16, 2018 10:56:48 GMT -5
How perfect would this be? UTHR says "We are putting 3 drugs on Technosphere"! Then hands Mannkind 120 Million dollars plus royalties. 😁😉🤑 If we get three more drugs you’re about 50 million short:-) This is definitely one example where the sun of the parts is greater than the whole. |
|
|
|
Post by falconquest on Sept 16, 2018 17:25:30 GMT -5
Lol....Correct If not big, just more clarification on revenues. How perfect would this be? UTHR says "We are putting 3 drugs on Technosphere"! Then hands Mannkind 120 Million dollars plus royalties. 😁😉🤑 That would be perfect........if accepted in the marketplace. We have to remember that just because Technosphere is used with other compounds it doesn't mean it will be accepted in the marketplace. If it is successful then we will realize the dream of Al Mann. I want to see revenue. Show me the revenue! |
|
